托法替布治疗无肌病性皮肌炎相关间质性肺疾病 - Suppr

Suppr

超能文献

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

作者信息

Chen Zhiwei, Wang Xiaodong, Ye Shuang

机构信息

Renji Hospital South Campus, Shanghai, China

出版信息

N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.

DOI:10.1056/NEJMc1900045

PMID:31314977

Abstract

摘要

相似文献

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.

Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119. doi: 10.1093/rheumatology/key188.

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.

Intern Med. 2024 Sep 15;63(18):2571-2578. doi: 10.2169/internalmedicine.2915-23. Epub 2024 Feb 12.

Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.

Mod Rheumatol Case Rep. 2021 Jan;5(1):76-81. doi: 10.1080/24725625.2020.1816674. Epub 2020 Sep 14.

Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.

Scand J Rheumatol. 2018 Jul;47(4):334-335. doi: 10.1080/03009742.2017.1369155. Epub 2017 Oct 18.

Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.

Ann Rheum Dis. 2023 Nov;82(11):1499-1501. doi: 10.1136/ard-2023-223919. Epub 2023 Jun 6.

Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.

Clin Immunol. 2020 Jun;215:108451. doi: 10.1016/j.clim.2020.108451. Epub 2020 Apr 29.

Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.

J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577. doi: 10.1097/RHU.0000000000000984.

Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.

J Med Case Rep. 2024 Sep 28;18(1):471. doi: 10.1186/s13256-024-04793-9.

Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.

Medicine (Baltimore). 2020 Sep 11;99(37):e21943. doi: 10.1097/MD.0000000000021943.

引用本文的文献

Characteristics and Outcomes of Diffuse Interstitial Pneumonias Discovered in the ICU: A Retrospective Monocentric Study-The "IPIC" (Interstitial Pneumonia in Intensive Care) Study.

Diagnostics (Basel). 2025 Aug 9;15(16):1995. doi: 10.3390/diagnostics15161995.

A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy.

Front Immunol. 2025 Aug 7;16:1568338. doi: 10.3389/fimmu.2025.1568338. eCollection 2025.

Severe laryngeal oedema unexpectedly observed during bronchoscopy in a patient with anti-MDA5-positive dermatomyositis.

BMJ Case Rep. 2025 Aug 11;18(8):e266696. doi: 10.1136/bcr-2025-266696.

Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.

Semin Immunopathol. 2025 Aug 6;47(1):32. doi: 10.1007/s00281-025-01054-9.

Dazukibart for dermatomyositis: expanding the therapeutic arsenal.

Ann Transl Med. 2025 Jun 27;13(3):24. doi: 10.21037/atm-25-44. Epub 2025 Jun 24.

Anti-interferon-α antibodies associate with disease activity and prognosis in anti-MDA5-positive dermatomyositis.

Arthritis Res Ther. 2025 Jul 2;27(1):133. doi: 10.1186/s13075-025-03600-0.

Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.

Biomedicines. 2025 Jun 13;13(6):1463. doi: 10.3390/biomedicines13061463.

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease.

J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjaf087.

JAK-STAT Signaling in Autoimmunity and Cancer.

Immunotargets Ther. 2025 May 11;14:523-554. doi: 10.2147/ITT.S485670. eCollection 2025.

Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment.

Curr Rheumatol Rep. 2025 May 5;27(1):23. doi: 10.1007/s11926-025-01188-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验